These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34041707)

  • 61. The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: Observations and recommendations.
    Klein K; Stolk P; De Bruin ML; Leufkens HGM; Crommelin DJA; De Vlieger JSB
    Eur J Pharm Sci; 2019 May; 133():228-235. PubMed ID: 30953753
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Marketing of medicinal products in the European Community. The Mutual Recognition and Decentralised Procedures].
    Bachmann P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):722-30. PubMed ID: 18560780
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tipranavir: PNU 140690, tipranivir.
    Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison.
    Reichert JM; Healy EM
    Eur J Pharm Biopharm; 2001 Jan; 51(1):1-7. PubMed ID: 11154897
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
    Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
    J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016.
    Morant AV; Jagalski V; Vestergaard HT
    Clin Transl Sci; 2019 Jul; 12(4):361-370. PubMed ID: 30681284
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Harmonising and competing for medicines regulation: how healthy are the European Union's systems of drug approval?
    Abraham J; Lewis G
    Soc Sci Med; 1999 Jun; 48(11):1655-67. PubMed ID: 10400264
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmaceutical biotechnology products approved within the European Union.
    Walsh G
    Eur J Pharm Biopharm; 2003 Jan; 55(1):3-10. PubMed ID: 12551698
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
    Nagai S; Ozawa K
    Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA.
    Dalla Torre Di Sanguinetto S; Heinonen E; Antonov J; Bolte C
    Ther Innov Regul Sci; 2019 Jan; 53(1):86-94. PubMed ID: 29714594
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Environmental risk assessment of advanced therapies containing genetically modified organisms in the EU.
    Whomsley R; Palmi Reig V; Hidalgo-Simon A
    Br J Clin Pharmacol; 2021 Jun; 87(6):2450-2458. PubMed ID: 33600022
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union.
    Hoekman J; Boon W
    Soc Sci Med; 2019 Feb; 222():76-83. PubMed ID: 30605802
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Determinants for successful marketing authorisation of orphan medicinal products in the EU.
    Putzeist M; Heemstra HE; Garcia JL; Mantel-Teeuwisse AK; Gispen-De Wied CC; Hoes AW; Leufkens HG
    Drug Discov Today; 2012 Apr; 17(7-8):352-8. PubMed ID: 22094244
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use.
    Cilia M; Ruiz S; Richardson P; Salmonson T; Serracino-Inglott A; Wirth F; Borg JJ
    AAPS PharmSciTech; 2018 Feb; 19(2):489-511. PubMed ID: 29027130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.